Almohanad Alkayyal

Title: The Innovative Contributions of Almohanad Alkayyal

Introduction

Almohanad Alkayyal is a notable inventor based in Ottawa, Canada. He has made significant strides in the field of cancer treatment through his innovative research and development. His work focuses on utilizing oncolytic viruses to enhance therapeutic outcomes for cancer patients.

Latest Patents

Alkayyals' most recent patent is titled "Oncolytic rhabdovirus expressing IL12." This patent discloses an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. The patent also outlines a method for treating cancer in patients using this oncolytic recombinant Maraba virus. Furthermore, it provides details on a tumor cell infected with the oncolytic rhabdovirus for use as an infected cell vaccine (ICV) in cancer treatment.

Career Highlights

Almohanad Alkayyal is associated with Turnstone Limited Partnership, where he continues to contribute to groundbreaking research in oncology. His dedication to advancing cancer therapies has positioned him as a key figure in the field.

Collaborations

Alkayyals' work is complemented by collaborations with esteemed colleagues such as Rebecca Auer and John Cameron Bell. Their combined expertise fosters an environment of innovation and progress in cancer research.

Conclusion

Almohanad Alkayyal's contributions to the field of cancer treatment through his innovative patent and collaborative efforts highlight his commitment to improving patient outcomes. His work exemplifies the potential of oncolytic viruses in modern medicine.